Tokyo, 10/15/2026 | Press Release | Medical Systems Olympus Introduces CADDIE™ PLUS, Expanding AI Support Across the Colonoscopy Procedure

The next generation of Olympus’ cloud-based colonoscopy AI now classifies polyp size and tracks withdrawal time in real-time, supporting clinicians in finding lesions that matter most and monitoring procedure quality.

Olympus Corporation (Olympus), a global MedTech company committed to advancing endoscopy-enabled care, today announced the introduction of CADDIE™ PLUS, the next generation of its cloud-based OLYSENSE™ AI solution for colonoscopy. Building on CADDIE™’s lesion detection and characterization capabilities, CADDIE PLUS adds real-time polyp size classification and Live Net Withdrawal Time to provide endoscopists with additional information during the procedure to support lesion assessment and colonoscopy quality. First shown at UEG (United European Gastroenterology) Week 2026 in Barcelona, CE-marked1 CADDIE PLUS will be available beginning in November 2026 in 17 European countries where CADDIE is currently offered.

  • Teilen:

Supporting better detection and quality during colonoscopy

The CADDIE PLUS application is the latest addition to OLYSENSE, Olympus’ connected digital platform designed to bring clinical AI, procedure data, reporting, and workflow solutions together across GI endoscopy. Through OLYSENSE, Olympus aims to move beyond stand-alone detection and characterization toward clinical impact across the full colonoscopy pathway: from detecting what matters to enabling AI-assisted lesion assessment, from supporting procedure quality to providing actionable post-procedure insights, all with the goal of helping clinicians make more informed decisions and ultimately supporting better patient outcomes.

CADDIE PLUS displaying “Polyp Size Classification” and “Net Withdrawal Time”

Finding precancerous lesions during colonoscopy and determining appropriate follow-up are central to colorectal cancer prevention. CADDIE PLUS builds on the OLYSENSE CAD/AI solution CADDIE, whose detection performance was demonstrated in the EAGLE randomized controlled trial: compared with standard colonoscopy, CADDIE increased the number of sessile serrated lesions detected per colonoscopy by 230 %, large adenomas greater than 10 mm detected per colonoscopy by 93 %, and absolute adenoma detection rate by 7.3 percentage points (43.2 % versus 35.9 %).2

“Colorectal cancer prevention starts with high-quality colonoscopy and the ability to detect and appropriately assess precancerous lesions,” said Miquel Àngel García, Executive Vice President & General Manager Gastrointestinal, Olympus Corporation. “CADDIE PLUS builds on the clinical capabilities of CADDIE by providing additional information during the procedure, while extending the role of OLYSENSE in supporting quality and consistency across the colonoscopy pathway.”

New capabilities during and after the procedure

CADDIE PLUS retains CADDIE’s detection and characterization capabilities and adds two new intraprocedural capabilities: Polyp size classification indicates whether a detected polyp is below or above the clinically relevant 10 mm threshold, providing additional information to support assessment and management. Live Net Withdrawal Time displays live and net withdrawal time during the procedure to support adherence to established European Society of Gastrointestinal Endoscopy (ESGE) quality standards. Withdrawal time is an established colonoscopy quality measure; ESGE recommends a minimum mean withdrawal time of six minutes, because a careful, unhurried withdrawal is linked to higher adenoma detection.3

Following the procedure, associated Computer-Aided Metrics (CAMs), a separate, standalone non-medical post-procedure software, automatically presents seven important procedure metrics, including total endoscope time, gross and net withdrawal time, cleaning and therapy time, and confirmation of caecum and retroflexion documentation. The metrics are generated without requiring additional steps from the care team.

“Finding the lesions that matter, and knowing their size, shapes what happens next for each patient, including when they need to return for surveillance,” said Dr Edward Seward, University College London Hospital. “Seeing polyp size and withdrawal time during the procedure helps us consistently meet the quality standards that matter most for our patients.”

Advancing intelligent endoscopy through AI

The European launch of CADDIE PLUS at UEG Week 2026 marks another step in Olympus’ broader ambition to deliver continuous innovation through the OLYSENSE Platform. The platform’s cloud-enabled architecture is designed to support connectivity, intelligence and scalability as additional capabilities become available. The OLYSENSE AI solutions operate within an ISO/IEC 27001-certified Information Security Management System (ISMS), providing hospital IT teams with independent assurance that information security is managed according to internationally recognized standards.

“AI is revolutionizing every industry, unlocking human potential and empowering us for a better future. Olympus equipment is used to treat millions of patients each year and OLYSENSE is a paradigm shift in the way doctors access AI and enhance patient care,” said Peter Mountney, Global VP of Artificial Intelligence, Olympus Corporation.

CADDIE PLUS will be available beginning in November 2026 in 17 European countries* where CADDIE is currently offered. CADDIE PLUS is not available in the United States. Product availability is subject to local regulatory requirements.

Visitors to UEG Week 2026, October 17 to 20 in Barcelona, can experience the solution at the Olympus booth in Hall 7, Booth 53.

Disclaimer

  • The contents of this press release are aimed at healthcare professionals only.
  • As medical knowledge is constantly growing, technical modifications or changes of the product design, product specifications, accessories and/or service offerings may be required.
  • The OLYSENSE CAD/AI portfolio is currently offered in the following 17 European countries: Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
  • Healthcare professionals mentioned in this press release have a business relationship with Olympus.
  • All trademarks and registered trademarks are the property of their respective owners.

About OLYSENSE

OLYSENSE is Olympus' unified GI digital platform that connects the people, technologies, and information behind GI procedures. Designed as a connected and continuously evolving platform, OLYSENSE hosts applications that are being developed to help GI departments work more efficiently, support informed decision-making, and continuously evolve to support care teams to advance patient care while staying ready for what's next. The platform hosts both non-medical and CE-marked medical software applications. CE-marked applications include CADDIE, CADDIE PLUS, CADU™, and SMARTIBD™, with future capabilities subject to development and applicable regulatory approvals.

About Olympus

At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit the Olympus website and follow the Olympus LinkedIn account.

Manufactured by

Odin Medical Limited (Trading as Odin Vision)
74 Rivington Street
EC2A 3AY, London, United Kingdom

1 CE certification issued by Berlin Cert GmbH (Notified Body 0633).

2 Kader R, et al. “A novel cloud-based artificial intelligence for real-time detection of colorectal neoplasia: a randomized controlled trial (EAGLE).” npj Digital Medicine (2025). The EAGLE trial was funded and sponsored by Odin Medical Ltd., an Olympus company. The EAGLE trial evaluated CADDIE and measured detection endpoints; it did not evaluate longer-term patient outcomes; data are ratios of lesions per colonoscopy versus standard of care, or absolute percentage-point difference for adenoma detection rate.

3 Kaminski MF, et al. “Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative.” Endoscopy 2017;49:378–397.

For questions or additional information, please contact:

Female Contact Icon

Mia Hatzis

Communications Business Partner Gastrointestinal Solutions

Olympus Corporation

Tel.: +1-484-788-3977
E-Mail: mia.hatzis@olympus.com